Prestige Consumer Healthcare (PBH) Change in Receivables (2010 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Change in Receivables came in at -$495000.0 in Q4 2025, down 107.84% year-on-year from $6.3 million in Q4 2024, and down 101.65% quarter-over-quarter from $29.9 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Change in Receivables (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Change in Receivables history runs 16 years deep, the most recent figure standing at -$495000.0 for Q4 2025.
- On a quarterly basis, Change in Receivables fell 107.84% year-over-year to -$495000.0 in Q4 2025; TTM through Dec 2025 was $27.3 million, a 385.15% increase from a year earlier, with the FY2025 full-year figure at $16.3 million, up 158.26% from the prior year.
- Change in Receivables retreated to -$495000.0 in Q4 2025 per PBH's latest filing, from $29.9 million in the prior quarter.
- Across five years, Change in Receivables topped out at $29.9 million in Q3 2025 and bottomed at -$27.3 million in Q2 2025.
- The 5-year median for Change in Receivables is $2.0 million (2022), against an average of $3.7 million.
- Across the five-year window, Change in Receivables tumbled 824.98% in 2024 and surged 3726.04% in 2025, its largest moves.
- Year by year, Change in Receivables stood at -$12.5 million in 2021, then jumped by 170.56% to $8.8 million in 2022, then rose by 29.88% to $11.4 million in 2023, then plunged by 44.74% to $6.3 million in 2024, then slumped by 107.84% to -$495000.0 in 2025.
- Per Business Quant, the three latest PBH Change in Receivables figures stand at -$495000.0 (Q4 2025), $29.9 million (Q3 2025), and -$27.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | -495,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -495,000.00 |
| Dec 31, 2025 | -495,000.00 |
| Sep 30, 2025 | 29.92 Mn |
| Sep 30, 2025 | 29.92 Mn |
| Jun 30, 2025 | -27.34 Mn |
| Jun 30, 2025 | -27.34 Mn |
| Mar 31, 2025 | 25.20 Mn |
| Mar 31, 2025 | 25.20 Mn |
| Dec 31, 2024 | 6.32 Mn |
| Dec 31, 2024 | 6.32 Mn |
| Sep 30, 2024 | -8.82 Mn |
| Sep 30, 2024 | -8.82 Mn |
| Jun 30, 2024 | -6.37 Mn |
| Jun 30, 2024 | -6.37 Mn |
| Mar 31, 2024 | -695,000.00 |
| Mar 31, 2024 | -695,000.00 |
| Dec 31, 2023 | 11.43 Mn |
| Dec 31, 2023 | 11.43 Mn |
| Sep 30, 2023 | 1.22 Mn |
| Sep 30, 2023 | 1.22 Mn |